Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea
In Vivo. 2019 Nov-Dec;33(6):2191-2198. doi: 10.21873/invivo.11721.
BACKGROUND/AIM: This study evaluated whether the lymphocyte tolerance factor (LTF) was an indicator of radiation tolerance of lymphocytes (RTL) using the relative lymphocyte count (RLC), and considering clinical outcomes.
A total of 92 cervical cancer patients treated with concurrent chemoradiotherapy (CCRT) were analysed. RLC0 was pre-treatment RLC, and RLC1, and RLC2 were at the first and second week of CCRT, respectively. LTF1 was RLC1:RLC2. LTF2 was the dimension of the convex or concave shape comprising the three RLC vertexes. Patients were divided into three groups: good RTL group, low LTF1; moderate RTL group, high LTF1 and low LTF2; and poor RTL group, high LTF1 and high LTF2.
Patients with good tumour response to radiotherapy were mostly included in the good RTL group than in the other groups. The poor RTL group had lower 3-year progression-free survival (57.1% vs. 83.8% and 82%, p=0.01) and 5-year disease-specific survival (71.8% vs. 90.4% and 94.9%, p=0.062) rates than the moderate and good RTL groups. Multivariate analyses showed that poor RTL was a significant survival predictor.
The poor RTL group according to LTF is a potential predictor of clinical outcome.
背景/目的：本研究通过相对淋巴细胞计数（RLC）评估淋巴细胞耐辐射因子（LTF）是否为淋巴细胞耐辐射性（RTL）的指标，并考虑临床结局。
共分析了 92 例接受同期放化疗（CCRT）的宫颈癌患者。RLC0 为治疗前 RLC，RLC1 和 RLC2 分别为 CCRT 第一周和第二周的 RLC。LTF1 为 RLC1:RLC2。LTF2 为包含三个 RLC 顶点的凸或凹形状的维度。患者分为三组：RTL 良好组，低 LTF1；中等 RTL 组，高 LTF1 和低 LTF2；以及 RTL 较差组，高 LTF1 和高 LTF2。
放疗反应良好的患者大多归入 RTL 良好组，而不是其他组。RTL 较差组的 3 年无进展生存率（57.1%比 83.8%和 82%，p=0.01）和 5 年疾病特异性生存率（71.8%比 90.4%和 94.9%，p=0.062）均低于中 RTL 和良好 RTL 组。多变量分析表明，较差 RTL 是生存的显著预测因素。
根据 LTF 划分的 RTL 较差组是临床结局的潜在预测因素。
